Celgene Reaches New 52-Week High (CELG)

NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Tuesday as it is currently trading at $76.14, above its previous 52-week high of $76.09 with 3.3 million shares traded as of 4 p.m. ET. Average volume has been 3.4 million shares over the past 30 days.

Celgene has a market cap of $32.86 billion and is part of the health care sector and drugs industry. Shares are up 11.2% year to date as of the close of trading on Monday.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. The company has a P/E ratio of 26.4, below the average drugs industry P/E ratio of 31.1 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Celgene Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks